Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Pharmaceutical sales up 10% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly
3Q Revenues: $5.7 billion (+9%)
3Q Earnings: $556 million (-29%)
YTD Revenues: $16.7 billion (+8%)
YTD Earnings: $1.5 billion (-26%)
Comments: Pharmaceutical revenue in the quarter grew 10%. New product revenue, composed of Trulicity, Basaglar, Taltz, Jardiance, Lartruvo, Cyramza, Olumiant and Portrazza, drove 14% volume growth and represented nearly 22% of total revenue. Trulicity revenue was $527.7 million, up 117%. Cyramza revenue was $196.0 million, up 23% Taltz sales were $151.3 million, an increase of $6.9 million compared with 2Q17. Basaglar sales were $145.7 million, an increase of $55.7 million. Jardiance sales were $127.2 million, up 168%. Humalog revenue increased 9% in the quarter to $696.2 million. Cialis sales were down 4% to $564.9 million due to decreased demand. Alimta sales were $514.5 million, down 10%. Forteo sales were $441.7 million, up 13% driven by higher realized prices. Humulin revenue was down 7% to $300.5 million driven by increased volume, partially offset by lower realized prices.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters